Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JayjayUSA12007on Jun 09, 2018 2:29pm

213 Views

Post# 28150140

RE:Trogarzo already close to 200 patients

SPCEO1 wrote:
"Total prescriptions are now close to 200 vs. 100 in mid-May." and "Taimed sees substantial demand for Trogarzxo in 2H18 and has placed substantial orders at its CMO partner Wuxi Biologics".

Sales launched by end of April. By mid-May, there were 100 patients prescribed. We are now at 1st week of June and close to 200 patients. So, the rate of patients prescribed is approximately 100 every 2 weeks.
At this rate, by end of 2018, 1,200 patients on Trogarzo would seem attainable. I believe this number is consistent with Fuzeon launch.

Bullboard Posts

What will the U.S. election results mean for Canada?